Low-doses aspirin in the primary prevention of cardiovascular disease in patients with diabetes: Meta-analysis stratified by baseline cardiovascular risk.

Date publication

janvier 2022

Journal

Diabetes & metabolic syndrome

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno

Tous les auteurs :
Masson W, Barbagelata L, Lavalle-Cobo A, Lobo M, Masson G, Nogueira JP, Vergès B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35030453

Résumé

The aim of this meta-analysis was to analyze the risks and benefits of low-dose aspirin in patients with T2D without cardiovascular conditions according to the baseline cardiovascular risk.

Mots clés

Aspirin, Cardiovascular risk, Major cardiovascular events, Type 2 diabetes

Référence

Diabetes Metab Syndr. 2022 Jan 8;16(1):102391